ARTICLE | Company News
Cue Biopharma in autoimmune deal with Merck
November 16, 2017 8:23 PM UTC
Merck & Co. Inc. (NYSE:MRK) partnered with Cue Biopharma Inc. (Cambridge, Mass.) to develop biologics to treat autoimmune diseases.
Cue will receive an undisclosed upfront payment, and will be eligible for up to $374 million in milestones, plus tiered royalties...